Sales

57,987

62,142

120,129

100%

5,636

9,633

15,269

Cost of sales

12,104

12,751

24,855

 21%

   867

2,037

  2,904

Gross margin

45,883

49,391

95,274

79%

4,769

7,596

12,365

Gross margin percentage

79.1%

79.5%

79.3%

SG&A expense

8,090

10,645

18,735

15%

1,023

1,815

2,838

R&D expense

5,181

5,562

10,743

9%

326

518

844

Amortization expense

288

282

570

-

(115)

(122)

(237)

Interest expense

0

0

-

(268)

(815)

(1,083)

Interest income

(2,998)

(3,252)

(6,250)

(5%)

(1,322)

(1,296)

(2,618)

Other non-operating ex., net

     569

      573

  1,142

   1%

      84

     145

     229

11,130

13,810

24,940

 20%

(272)

    245

    (27)

Earnings before income taxes

34,753

35,581

70,334

59%

5,041

7,351

12,392

Income taxes

11,681

11,942

23,623

 20%

1,600

2,375

 3,975

23,072

23,639

46,711

 39%

3,441

4,976

 8,417

Diluted earnings per share

.58

.60

1.18

Weighted average diluted shares outstanding

39,587

39,497

39,542

Sales

3,657

3,972

7,629

100%

155

146

301

Cost of sales

2,261

2,276

4,537

  59%

163

129

292

Gross margin

1,396

1,696

3,092

41%

(8)

17

9

Gross margin percentage

38.2%

42.7%

40.5%

SG&A expense

467

487

954

13%

69

48

117

R&D expense

179

194

373

5%

(1)

4

3

Interest, net

(120)

(125)

 (245)

(3%)

(39)

(30)

(69)

  526

  556

1,082

15%

  29

  22

  51

Pretax result

  870

1,140

2,010

26%

(37)

 (5)

(42)

Sales

45,328

46,576

91,904

100%

3,707

6,503

10,210

Intersegment sales

(6,447)

(7,433)

(13,880)

  (748)

  (786)

 (1,534)

38,881

39,143

78,024

2,959

5,717

8,676

Cost of sales

8,997

9,612

18,609

20%

515

1,929

2,444

Intersegment sales

(6,174)

(7,430)

(13,604)

(650)

 (995)

 (1,645)

2,823

2,182

5,005

(135)

934

799

Gross margin

36,058

36,961

73,019

80%

3,094

4,783

7,877

Gross margin percentage

80.2%

79.4%

79.8%

SG&A expense

4,624

5,534

10,158

11%

611

870

1,481

R&D expense

5,002

5,368

10,370

11%

327

514

841

Amortization expense

288

282

570

1%

(115)

(122)

(237)

Interest, net

(1,257)

(1,309)

(2,566)

(3%)

(662)

(587)

(1,249)

Exchange loss/(gain)

       34

       12

      46

     --

    34

     12

       46

  8,691

  9,887

18,578

20%

  195

   687

    882

Pretax result

27,367

27,074

54,441

60%

2,899

4,096

 6,995

Sales

7,605

9,301

16,906

100%

735

1,450

2,185

Cost of sales

3,455

4,053

  7,508

 44%

170

  287

   457

Gross margin

4,150

5,248

9,398

56%

565

1,163

1,728

Gross margin percentage

54.6%

56.4%

55.6%

SG&A expense

1,114

1,276

2,390

14%

40

40

80

Interest income

(683)

(773)

(1,456)

(8%)

(273)

(293)

(566)

Exchange loss/(gain)

  (96)

  (81)

  (177)

(1%)

(174)

  (17)

(191)

  335

   422

    757

  5%

(407)

(270)

(677)

Pretax result

3,815

4,826

 8,641

51%

  972

1,433

2,405

Sales

15,449

19,027

34,476

100%

2,522

3,770

6,292

Cost of sales

 7,020

 8,293

15,313

  44%

   839

   974

1,813

Gross margin

8,429

10,734

19,163

56%

1,683

2,796

4,479

Gross margin percentage

54.6%

56.4%

55.6%

SG&A expense

2,262

2,599

4,861

14%

242

194

436

Interest income

(1,387)

(1,576)

(2,963)

(9%)

(616)

(643)

(1,259)

Exchange loss

(198)

  (165)

  (363)

(1%)

(345)

  (39)

  (384)

   677

    858

 1,535

  5%

(719)

(488)

(1,207)

Pretax result

7,752

 9,876

17,628

51%

2,402

3,284

 5,686

Interest income

234

242

476

5

36

41

Rental income

     67

     111

    178

(232)

(130)

(362)

301

353

654

(227)

(94)

(321)

SG&A expense

737

2,025

2,762

101

703

804

Interest expense

--

--

--

(268)

(815)

(1,083)

Other-Building expenses

544

600

1,144

34

51

85

Other-Hemerus losses

131

113

244

4

(10)

(6)

Other-Nephromics losses

     125

    124

     249

  125

       1

   126

  1,537

  2,862

  4,399

   (4)

  (70)

  (74)

Pretax result

(1,236)

(2,509)

(3,745)

(223)

  (24)

(247)